## Dion R Brocks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11628/publications.pdf

Version: 2024-02-01

107 papers 3,445 citations

32 h-index 54 g-index

109 all docs

109 docs citations

109 times ranked 4104 citing authors

#	Article	IF	CITATIONS
1	Piecing together human adult comparative pharmacokinetic trials and rodent studies: What happens to drug clearance in obesity?. Journal of Pharmacy and Pharmaceutical Sciences, 2022, 25, 41-68.	0.9	4
2	Analysis of cycloheximide in rat specimens using liquid chromatography with tandem mass spectrometry detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1190, 123112.	1.2	1
3	Online interviews for the selection of applicants for admission into an entry to practice program in pharmacy: Relationship to performance and student perspectives. Currents in Pharmacy Teaching and Learning, 2021, 13, 616-622.	0.4	4
4	Does a sudden shift of testing format from closed-book to open-book change the characteristics of test scores on summative final exams?. Currents in Pharmacy Teaching and Learning, 2021, 13, 1174-1179.	0.4	3
5	Liquid Chromatography Tandem Mass Spectrometric Analytical Method for Study of Colchicine in Rats Given Low Doses. Processes, 2021, 9, 2007.	1.3	4
6	Dronedarone: the effect of diet-induced obesity on its metabolism and experimental hyperlipidemia on its metabolism and tissue distribution in the rat. Canadian Journal of Physiology and Pharmacology, 2020, 98, 177-181.	0.7	1
7	Dietary-Induced Obesity, Hepatic Cytochrome P450, and Lidocaine Metabolism: Comparative Effects of High-Fat Diets in Mice and Rats and Reversibility of Effects With Normalization of Diet. Journal of Pharmaceutical Sciences, 2020, 109, 1199-1210.	1.6	8
8	Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring. Research in Pharmaceutical Sciences, 2020, 15, 503.	0.6	10
9	Rectus sheath single-injection blocks: a study to quantify local anaesthetic absorption using serial ultrasound measurements and lidocaine serum concentrations. Journal of Pharmacy and Pharmacology, 2019, 71, 1282-1290.	1.2	7
10	Examining the relationship between prerequisite grades and types of academic performance in pharmacy school. Currents in Pharmacy Teaching and Learning, 2018, 10, 695-700.	0.4	12
11	Identification and Characterization of Novel Receptor-Interacting Serine/Threonineâ€Protein Kinase 2 Inhibitors Using Structural Similarity Analysis. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 354-367.	1.3	22
12	Lymphatic Drug Absorption via the Enterocytes: Pharmacokinetic Simulation, Modeling, and Considerations for Optimal Drug Development. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 254s-270s.	0.9	28
13	Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 32s-47s.	0.9	6
14	Dietary-Induced Obesity and Changes in the Biodistribution and Metabolism of Amiodarone in the Rat. Journal of Pharmaceutical Sciences, 2018, 107, 2938-2945.	1.6	8
15	Pharmacokinetics of metformin in the rat: assessment of the effect of hyperlipidemia and evidence for its metabolism to guanylurea. Canadian Journal of Physiology and Pharmacology, 2017, 95, 530-538.	0.7	14
16	The Obesogenic Potency of Various High-Caloric Diet Compositions in Male Rats, and Their Effects on Expression of Liver and Kidney Proteins Involved in Drug Elimination. Journal of Pharmaceutical Sciences, 2017, 106, 1650-1658.	1.6	8
17	Comments on "Effects of Obesity and Leptin Deficiency on Morphine Pharmacokinetics in a Mouse Model―by Dalesio et al, Anesth Analg. 2016;123:1611–1617. Anesthesia and Analgesia, 2017, 125, 361-361.	1.1	O
18	A High-Performance Liquid Chromatography Assay Method for the Determination of Lidocaine in Human Serum. Pharmaceutics, 2017, 9, 52.	2.0	20

#	Article	IF	Citations
19	Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes. Frontiers in Endocrinology, 2017, 8, 154.	1.5	6
20	The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. Biopharmaceutics and Drug Disposition, 2016, 37, 345-351.	1.1	12
21	Ketoconazole Stereoisomers Differentially Induce Cytochrome P450 1A1 Between Human Hepatoma HepG2 and Mouse Hepatoma Hepa1c1c7 Cells. Journal of Pharmaceutical Sciences, 2016, 105, 1318-1326.	1.6	1
22	uSIMPK. An Excel for Windows-based simulation program for instruction of basic pharmacokinetics principles to pharmacy students. Computer Methods and Programs in Biomedicine, 2015, 120, 154-163.	2.6	8
23	Role of Environmental Factors in the Development of Pediatric Eosinophilic Esophagitis. Digestive Diseases and Sciences, 2015, 60, 3364-3372.	1.1	44
24	Effects of serum lipoproteins on cyclosporine A cellular uptake and renal toxicity in vitro. Canadian Journal of Physiology and Pharmacology, 2014, 92, 140-148.	0.7	11
25	Breast milk concentrations of amiodarone, desethylamiodarone, and bisoprolol following shortâ€ŧerm drug exposure: Two case reports. Journal of Clinical Pharmacology, 2014, 54, 828-831.	1.0	8
26	Pharmacokinetics of dronedarone in rat using a newly developed highâ€performance liquid chromatographic assay method. Biomedical Chromatography, 2014, 28, 1070-1074.	0.8	6
27	A liquid chromatography–mass spectrometric method for the quantification of azithromycin in human plasma. Biomedical Chromatography, 2013, 27, 1012-1017.	0.8	7
28	Effect of Rat Serum Lipoproteins on mRNA Levels and Amiodarone Metabolism by Cultured Primary Rat Hepatocytes. Journal of Pharmaceutical Sciences, 2013, 102, 262-270.	1.6	9
29	Pharmacokinetic Characterization of Intravenous Cyclosporine Treatment for Cardioprotection During Resuscitation of Asphyxiated Newborn Piglets. Pediatric Critical Care Medicine, 2013, 14, e156-e162.	0.2	0
30	The Single Dose Poloxamer 407 Model of Hyperlipidemia; Systemic Effects on Lipids Assessed Using Pharmacokinetic Methods, and its Effects on Adipokines. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 65.	0.9	36
31	Effect of gastric bypass surgery on azithromycin oral bioavailability. Journal of Antimicrobial Chemotherapy, 2012, 67, 2203-2206.	1.3	35
32	The effects of gastric bypass surgery on drug absorption and pharmacokinetics. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1505-1519.	1.5	48
33	Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 142-148.	2.0	33
34	Cyclosporine Treatment Reduces Oxygen Free Radical Generation and Oxidative Stress in the Brain of Hypoxia-Reoxygenated Newborn Piglets. PLoS ONE, 2012, 7, e40471.	1.1	11
35	Effect of serum lipoproteins on stereoselective halofantrine metabolism by rat hepatocytes. Chirality, 2012, 24, 558-565.	1.3	9
36	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer, 2012, 118, 1868-1876.	2.0	109

#	Article	IF	CITATIONS
37	Effect of Gastric Bypass Surgery on the Absorption and Bioavailability of Metformin. Diabetes Care, 2011, 34, 1295-1300.	4.3	87
38	Effect of hyperlipidemia on ketoconazole–midazolam drug–drug interaction in rat. Journal of Pharmaceutical Sciences, 2011, 100, 4986-4992.	1.6	9
39	A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer, 2011, 117, 4194-4200.	2.0	55
40	A liquid chromatography-mass spectrometry method for nicotine and cotinine; utility in screening tobacco exposure in patients taking amiodarone. Biomedical Chromatography, 2011, 25, 1124-1131.	0.8	15
41	The ability of polycyclic aromatic hydrocarbons to alter physiological factors underlying drug disposition. Drug Metabolism Reviews, 2011, 43, 457-475.	1.5	17
42	Metformin and Exercise in Type 2 Diabetes. Diabetes Care, 2011, 34, 1469-1474.	4.3	86
43	The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat. Xenobiotica, 2011, 41, 137-143.	0.5	12
44	Effect of bile and lipids on the stereoselective metabolism of halofantrine by rat evertedâ€intestinal sacs. Chirality, 2010, 22, 275-283.	1.3	8
45	An analytical method for cyclosporine using liquid chromatography–mass spectrometry. Biomedical Chromatography, 2010, 24, 148-153.	0.8	12
46	Effects of intestinal constituents and lipids on intestinal formation and pharmacokinetics of desethylamiodarone formed from amiodarone. Journal of Pharmacy and Pharmacology, 2010, 60, 1625-1632.	1.2	4
47	Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation. Journal of Pharmacy and Pharmacology, 2010, 54, 1049-1053.	1.2	18
48	High performance liquid chromatographic assay for the simultaneous determination of midazolam and ketoconazole in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 617-622.	1.4	16
49	The effect of CYP1A induction on amiodarone disposition in the rat. Journal of Pharmaceutical Sciences, 2010, 99, 539-548.	1.6	9
50	Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats. British Journal of Pharmacology, 2010, 161, 1427-1440.	2.7	13
51	Determination of Metformin in Human Plasma and Urine by High-Performance Liquid Chromatography Using Small Sample Volume and Conventional Octadecyl Silane Column. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 486.	0.9	38
52	Assessment of the Inactivation Potential of Desethylamiodarone on Human CYP1A1. Drug Metabolism Letters, 2010, 4, 9-14.	0.5	2
53	The effect of $\hat{I}^2$ -naphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes. Toxicology Letters, 2010, 195, 147-154.	0.4	21
54	Multiple Peaking Phenomena in Pharmacokinetic Disposition. Clinical Pharmacokinetics, 2010, 49, 351-377.	1.6	115

#	Article	IF	CITATIONS
55	Rate and Extent of Drug Accumulation after Multiple Dosing Revisited. Clinical Pharmacokinetics, 2010, 49, 421-438.	1.6	27
56	Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 90-95.	2.0	20
57	The effect of oral lipids and circulating lipoproteins on the metabolism of drugs. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1385-1398.	1.5	29
58	The effect of experimental hyperlipidemia on the stereoselective tissue distribution, lipoprotein association and microsomal metabolism of $(\hat{A}_{\pm})$ -halofantrine. Journal of Pharmaceutical Sciences, 2009, 98, 2516-2528.	1.6	16
59	Experimental Hyperlipidemia Causes an Increase in the Electrocardiographic Changes Associated With Amiodarone. Journal of Cardiovascular Pharmacology, 2009, 53, 1-8.	0.8	20
60	Polymeric Micellar Delivery Reduces Kidney Distribution and Nephrotoxic Effects of Cyclosporine A After Multiple Dosing. Journal of Pharmaceutical Sciences, 2008, 97, 1916-1926.	1.6	10
61	Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. Biopharmaceutics and Drug Disposition, 2008, 29, 159-166.	1.1	29
62	A stereospecific highâ€performance liquid chromatographic assay for the determination of ketoconazole enantiomers in rat plasma. Biomedical Chromatography, 2008, 22, 542-547.	0.8	26
63	Development of a liquid chromatography–mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 869, 31-37.	1.2	10
64	The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. International Journal of Pharmaceutics, 2008, 361, 78-86.	2.6	50
65	Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nature Reviews Drug Discovery, 2008, 7, 84-99.	21.5	209
66	Disposition of Drugs in Block Copolymer Micelle Delivery Systems. Clinical Pharmacokinetics, 2008, 47, 619-634.	1.6	72
67	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. Journal of Pharmacy and Pharmaceutical Sciences, 2008, 11, 147.	0.9	63
68	Induction of the NAD(P)H:quinone oxidoreductase 1 by ketoconazole and itraconazole: A mechanism of cancer chemoprotection. Cancer Letters, 2007, 258, 135-143.	3.2	15
69	Induction of Cytochrome P450 1A1 by Ketoconazole and Itraconazole but not Fluconazole in Murine and Human Hepatoma Cell Lines. Toxicological Sciences, 2007, 97, 32-43.	1.4	47
70	The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: Evidence of tissue-specific enantioselectivity in microsomal metabolism. Chirality, 2007, 19, 22-33.	1.3	9
71	A liquid chromatography–mass spectrometry assay method for simultaneous determination of amiodarone and desethylamiodarone in rat specimens. Biomedical Chromatography, 2007, 21, 284-290.	0.8	20
72	High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomedical Chromatography, 2007, 21, 546-552.	0.8	170

#	Article	IF	CITATIONS
73	A novel use of an in vitro method to predict the in vivo stability of block copolymer based nano-containers. Journal of Controlled Release, 2007, 122, 63-70.	4.8	22
74	The Influence of Hyperlipoproteinemia on in Vitro Distribution of Amiodarone and Desethylamiodarone in Human and Rat Plasma. Pharmaceutical Research, 2007, 24, 672-678.	1.7	21
75	Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function. AAPS Journal, 2006, 8, E672-E681.	2.2	25
76	The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharmaceutics and Drug Disposition, 2006, 27, 7-16.	1.1	44
77	Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharmaceutics and Drug Disposition, 2006, 27, 387-406.	1.1	128
78	DETERMINATION OF THE ENZYME(S) INVOLVED IN THE METABOLISM OF AMIODARONE IN LIVER AND INTESTINE OF RAT: THE CONTRIBUTION OF CYTOCHROME P450 3A ISOFORMS. Drug Metabolism and Disposition, 2006, 34, 43-50.	1.7	48
79	Development of a sensitive and specific liquid chromatography/mass spectrometry method for the quantification of cucurbitacin I (JSI-124) in rat plasma. Journal of Pharmacy and Pharmaceutical Sciences, 2006, 9, 158-64.	0.9	6
80	Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. Biomaterials, 2005, 26, 7251-7259.	5.7	123
81	Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharmaceutics and Drug Disposition, 2005, 26, 249-257.	1.1	78
82	A sensitive and specific high performance liquid chromatographic assay for milrinone in rat and human plasma using a commercially available internal standard and low sample volume. Journal of Pharmacy and Pharmaceutical Sciences, 2005, 8, 124-31.	0.9	7
83	Stereoselectivity in the Pharmacodynamics and Pharmacokinetics of the Chiral Antimalarial Drugs. Clinical Pharmacokinetics, 2003, 42, 1359-1382.	1.6	91
84	Stereoselective Pharmacokinetics and Pharmacodynamics of Anti-Asthma Agents. Annals of Pharmacotherapy, 2002, 36, 693-701.	0.9	28
85	Impact of Stereoselectivity on the Pharmacokinetics and Pharmacodynamics of Antiarrhythmic Drugs. Clinical Pharmacokinetics, 2002, 41, 533-558.	1.6	54
86	The Influence of Lipids on Stereoselective Pharmacokinetics of Halofantrine: Important Implications in Foodâ€Effect Studies Involving Drugs That Bind to Lipoproteins. Journal of Pharmaceutical Sciences, 2002, 91, 1817-1826.	1.6	45
87	Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: cardiac and plasma concentrations and plasma protein binding. Biopharmaceutics and Drug Disposition, 2002, 23, 9-15.	1.1	17
88	Metabolic acidosis: separation methods and biological relevance of organic acids and lactic acid enantiomers. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 781, 39-56.	1,2	65
89	Enhancement of Dissolution of Ethopropazine Using Solid Dispersions Prepared with Phospholipid and/or Polyethylene Glycol. Drug Development and Industrial Pharmacy, 2001, 27, 413-418.	0.9	18
90	Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. Biopharmaceutics and Drug Disposition, 2000, 21, 365-371.	1.1	18

#	Article	IF	Citations
91	The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins. Pharmaceutical Research, 2000, 17, 427-431.	1.7	27
92	Pharmacokinetics of ethopropazine in the rat after oral and intravenous administration., 1999, 20, 159-163.		2
93	Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons., 1999, 20, 165-169.		23
94	Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers. British Journal of Clinical Pharmacology, 1997, 44, 289-291.	1.1	16
95	Pharmacokinetics of Testosterone in Hypogonadal Men After Transdermal Delivery: Influence of Dose. Journal of Clinical Pharmacology, 1996, 36, 732-739.	1.0	33
96	Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Pharmaceutical Research, 1996, 13, 794-797.	1.7	13
97	A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 1995, 13, 911-918.	1.4	23
98	Pharmacokinetic Optimisation of the Treatment of Osteoarthritis. Clinical Pharmacokinetics, 1994, 26, 233-242.	1.6	5
99	Etodolac Clinical Pharmacokinetics. Clinical Pharmacokinetics, 1994, 26, 259-274.	1.6	57
100	Hematologic Disposition of Hydroxychloroquine Enantiomers. Journal of Clinical Pharmacology, 1994, 34, 1088-1097.	1.0	34
101	Influence of the route of administration on the pharmacokinetics of pirprofen enantiomers in the rat. Chirality, 1993, 5, 61-64.	1.3	7
102	The Stereoselective Pharmacokinetics of Etodolac in Young and Elderly Subjects, and After Cholecystectomy. Journal of Clinical Pharmacology, 1992, 32, 982-989.	1.0	25
103	Clinical Pharmacokinetics of Ketorolac Tromethamine. Clinical Pharmacokinetics, 1992, 23, 415-427.	1.6	116
104	Analytical and semi-preparative high-performance liquid chromatographic separation and assay of hydroxychloroquine enantiomers. Biomedical Applications, 1992, 581, 83-92.	1.7	48
105	Stereoselective Disposition of Etodolac Enantiomers in Synovial Fluid. Journal of Clinical Pharmacology, 1991, 31, 741-746.	1.0	32
106	Enantioselective Pharmacokinetics of Etodolac in the Rat: Tissue Distribution, Tissue Binding, and In Vitro Metabolism. Journal of Pharmaceutical Sciences, 1991, 80, 1058-1061.	1.6	27
107	Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers. Clinical Pharmacokinetics, 1990, 19, 197-217.	1.6	178